LigaChem Biosciences Inc. (KOSDAQ: 141080)
South Korea
· Delayed Price · Currency is KRW
117,600
-3,100 (-2.57%)
Nov 14, 2024, 9:00 AM KST
LigaChem Biosciences Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2019 | FY 2018 | 2017 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | 2017 - 2014 |
Net Income | -33,947 | -73,704 | -45,092 | -23,391 | 13,586 | -25,770 | Upgrade
|
Depreciation & Amortization | 4,848 | 4,672 | 4,118 | 3,049 | 3,865 | 2,780 | Upgrade
|
Loss (Gain) From Sale of Assets | -21.06 | -37.83 | -1.13 | 177.8 | 0.41 | -7 | Upgrade
|
Asset Writedown & Restructuring Costs | 260.2 | 260.2 | 301.66 | - | - | 11,465 | Upgrade
|
Loss (Gain) From Sale of Investments | 4,551 | 6,853 | 2,088 | 422.81 | -3,989 | -668.57 | Upgrade
|
Loss (Gain) on Equity Investments | -1,315 | -838.1 | -52.28 | -1,030 | - | - | Upgrade
|
Stock-Based Compensation | 15,782 | 4,478 | 3,104 | 1,380 | 545.5 | 683.12 | Upgrade
|
Provision & Write-off of Bad Debts | 6,117 | 5,021 | 9,810 | -121.97 | 1,945 | 58.86 | Upgrade
|
Other Operating Activities | -13,451 | -6,517 | 1,207 | 2,933 | -71.36 | 79.87 | Upgrade
|
Change in Accounts Receivable | 1,302 | -7,072 | 9,876 | -1,779 | 4,682 | -2,573 | Upgrade
|
Change in Inventory | -20.29 | 1.99 | 71.73 | 14.9 | -1,472 | 181.4 | Upgrade
|
Change in Accounts Payable | -627.89 | -163.21 | 439.25 | 290.72 | -567.26 | -561.91 | Upgrade
|
Change in Other Net Operating Assets | 73,353 | 4,809 | 6,996 | -23,996 | 5,589 | 1,574 | Upgrade
|
Operating Cash Flow | 56,831 | -62,236 | -7,136 | -42,049 | 24,113 | -12,758 | Upgrade
|
Capital Expenditures | -1,360 | -1,319 | -4,164 | -18,309 | -3,370 | -3,757 | Upgrade
|
Sale of Property, Plant & Equipment | 33.99 | 38.99 | - | 0.14 | 0.23 | 14.06 | Upgrade
|
Sale (Purchase) of Intangibles | -692.37 | -882.68 | -607.82 | -134.95 | -117.34 | -213.07 | Upgrade
|
Investment in Securities | -440,499 | 11,530 | -11,397 | -25,153 | 33,459 | -46,616 | Upgrade
|
Other Investing Activities | 0 | - | -0 | -347.47 | - | -13 | Upgrade
|
Investing Cash Flow | -442,517 | 9,367 | -16,169 | -43,944 | 29,971 | -50,585 | Upgrade
|
Short-Term Debt Issued | - | 9,147 | 2,700 | - | - | - | Upgrade
|
Long-Term Debt Issued | - | - | - | 8,235 | 2,337 | - | Upgrade
|
Total Debt Issued | 9,147 | 9,147 | 2,700 | 8,235 | 2,337 | - | Upgrade
|
Long-Term Debt Repaid | - | -9,380 | -2,888 | -206.91 | - | - | Upgrade
|
Total Debt Repaid | -9,473 | -9,380 | -2,888 | -206.91 | - | - | Upgrade
|
Net Debt Issued (Repaid) | -326.03 | -233.07 | -188.31 | 8,028 | 2,337 | - | Upgrade
|
Issuance of Common Stock | 474,666 | 3,207 | 3,390 | 3,290 | 265.72 | 60,466 | Upgrade
|
Repurchase of Common Stock | -4,879 | -4,879 | - | - | - | - | Upgrade
|
Other Financing Activities | -63.23 | -4.21 | -2.64 | -26.3 | -1.25 | 4,474 | Upgrade
|
Financing Cash Flow | 469,397 | -1,909 | 3,199 | 171,292 | 2,601 | 64,940 | Upgrade
|
Foreign Exchange Rate Adjustments | -20.56 | -133.4 | -1,869 | -7.9 | -19.29 | 1.72 | Upgrade
|
Net Cash Flow | 83,690 | -54,911 | -21,975 | 85,291 | 56,667 | 1,599 | Upgrade
|
Free Cash Flow | 55,471 | -63,555 | -11,300 | -60,358 | 20,743 | -16,515 | Upgrade
|
Free Cash Flow Margin | 72.78% | -186.13% | -33.82% | -187.70% | 36.07% | -65.43% | Upgrade
|
Free Cash Flow Per Share | 1763.26 | -2237.54 | -403.33 | -2501.88 | 863.87 | -783.62 | Upgrade
|
Cash Interest Paid | 538.99 | 498.69 | 287.84 | 51.86 | - | 93.6 | Upgrade
|
Cash Income Tax Paid | 519.45 | 1,091 | 385.68 | 82.06 | 504.03 | 66.62 | Upgrade
|
Levered Free Cash Flow | 54,546 | -51,371 | -2,928 | - | 16,281 | -12,201 | Upgrade
|
Unlevered Free Cash Flow | 54,900 | -51,041 | -2,749 | - | 16,297 | -12,122 | Upgrade
|
Change in Net Working Capital | -80,961 | 4,635 | -28,874 | - | -10,659 | 946.38 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.